Redox Control of Mesenchymal Stromal Cell-Mediated Immunoregulation in Rheumatoid Arthritis: From Licensing to Stromal Inflammaging
Background: Mesenchymal stromal cells (MSCs) are dynamic regulators of the immune response whose immunomodulatory functions are influenced by inflammatory cues. In rheumatoid arthritis (RA), acute inflammatory signals enhance MSC function through licensing, whereas chronic exposure to the inflammatory microenvironment promotes mitochondrial dysfunction, oxidative stress, senescence, and loss of immunoregulatory capacity. In parallel, fibroblast-like synoviocytes (FLS) undergo metabolic and mitochondrial reprogramming that promote inflammatory activation, apoptosis resistance, and tissue-destructive behavior. Methods: This structured narrative review examined the literature on MSC licensing and T-cell regulation in rheumatoid arthritis. A comprehensive literature search of ScienceDirect, Web of Science, and PubMed was conducted in September and November 2026 to identify relevant studies published between 1990 to 2026. Search terms included combinations of “mesenchymal stem/stromal cells”, “T-cells”, “rheumatoid arthritis”, “RA”, “priming/licensing”, “immunomodulation”, “mitochondrial dysfunction”, “metabolic reprogramming”, and “synovial environment”. Original research articles and reviews were included. Of 273 initially identified articles, 182 remained after duplicate removal, and 125 were included in the final analysis. Studies were considered eligible if they addressed relevant information on MSC licensing, MSC immunomodulation, mitochondrial metabolism, or stromal–immune interactions in RA. Evidence from human-derived cells and experimental arthritis models was considered. Mechanistic studies in non-RA models were included where they provided relevant insights into the underlying mechanisms of MSC licensing and T-cell regulation. Studies were excluded if they lacked sufficient relevance to RA, did not provide original experimental data, or contained insufficient mechanistic information. Screening was performed by S.S. and J.D. and evaluation was conducted separately before comparison. Results: Findings from human RA samples and experimental models suggest that inflammatory licensing can transiently enhance MSC-mediated immunosuppression through metabolic adaptation, whereas prolonged inflammation is associated with mitochondrial dysfunction, redox imbalance, and senescence. These changes may reduce the capacity of MSCs to suppress pathogenic T-cell responses. In parallel, RA-FLS exhibit altered glycolytic and lipid metabolism, mitochondrial dysfunction, and increased inflammatory and invasive behavior. These findings suggest that metabolic dysregulation may reinforce stromal–immune interactions that propagate synovitis; however, the precise mechanism has not been elucidated in RA patient-derived MSCs. Conclusions: This review provides an integrated framework linking inflammatory licensing, metabolic flexibility, mitochondrial homeostasis, and stromal–immune interactions to understand MSC immunoregulatory function in RA and the contribution of FLS to RA pathogenesis. Here, we highlighted processes contributing to persistent synovial inflammation and identified potential targets for therapeutic intervention. Strategies to preserve metabolic flexibility and mitochondrial homeostasis warrant further investigation, but mechanistic confirmation in human RA models and clinical studies is needed before potential therapies can be developed.
Authors
- Eva Roßmanith (ORCID: https://orcid.org/0000-0002-1489-8638)
- Michael Bonelli
- Michael Bernhard Fischer (ORCID: https://orcid.org/0000-0002-5876-0243)
- Julia Drescher
Institutions
- Universität für Weiterbildung Krems (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Cells
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/cells15222121
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Austrian Science Fund